Navigation Links
New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
Date:3/28/2008

Implantable Device Designed for Type-2 Diabetes Patients Who Are Overweight

and Do Not Respond to Current Oral Anti-Diabetic Treatments

Device Applies Electrical Stimulation to Stomach as Person Eats

NEW YORK, March 28 /PRNewswire/ -- New York-Presbyterian Hospital/Weill Cornell Medical Center is recruiting patients for a national clinical research study of an investigational implantable device designed to help those with type-2 diabetes who are overweight and do not respond to current oral anti- diabetic treatments.

The Tantalus(R) System is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation when a person eats. The device is implanted though a minimally invasive laparoscopic procedure that can be performed in an outpatient setting.

New York-Presbyterian/Weill Cornell is the first New York metro area medical center to recruit and actively enroll patients in this study. Diabetes affects more than one million New Yorkers.

"Even with current medications and lifestyle changes, controlling type-2 diabetes in patients who are overweight can be difficult. This new treatment potentially offers new hope for patients who have been unsuccessful in managing their diabetes and weight," says Dr. Louis Aronne, clinical site principal investigator, director of the Comprehensive Weight Control Program at New York-Presbyterian/Weill Cornell and clinical professor of medicine at Weill Cornell Medical College.

An earlier, smaller study published in the Journal of Obesity Surgery found that the device reduced hunger and body weight in morbidly obese patients. Improvements in blood pressure were also seen.

"The primary objective of the current study is to evaluate the safety and efficacy of the Tantalus in treating overweight patients with type-2 diabetes. The device's impact on weight loss, blood pressure and other clinical and metabolic parameters will also be studied," says Dr. Gregory F. Dakin, the study's co-principal investigator, bariatric and laparoscopic surgeon at New York-Presbyterian/Weill Cornell and assistant professor of surgery at Weill Cornell Medical College.

To be considered for the trial, patients must meet certain inclusion criteria, including a diagnosis of type-2 diabetes (treated with oral medications, only), a body mass index (BMI) between 28 and 45 kg/m2 and an age between 18 and 70 years. BMI can be determined by using an online calculator and entering weight and height information (one example here: http://www.nhlbisupport.com/bmi/).

New York-Presbyterian/Weill Cornell is one of thirty sites in the U.S. participating in the study, which is funded by MetaCure, the manufacturer of Tantalus. The device is currently CE-marked in Europe.

The national epidemic of type-2 diabetes, most often associated with being overweight, continues to accelerate and affects more than 20 million Americans. About one million new people are diagnosed with the disease annually. The most common form of diabetes, type-2 diabetes, left untreated, may result in damage to the eyes, kidneys, nerves or heart and lead to major health complications later in life, or to death.

For more information on and to be considered for the study, please call the study coordinator at (212) 583-1000 or email smw2004@med.cornell.edu.


'/>"/>
SOURCE MetaCure
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... know that PhRMA member companies invested $65.5 billion in research and ... generics and the supply chain account for 14 percent of total ... (7 percent)? Or that the United States ... high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for 1 ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
Breaking Medicine Technology:
(Date:7/27/2017)... ATLANTA, Ga. (PRWEB) , ... July 27, 2017 , ... ... Man native Sam Brand to the men’s pro squad as a stagiaire for the ... to make his professional debut on July 31st at the Tour of Utah. , ...
(Date:7/26/2017)... ... 26, 2017 , ... Written By: Ashley D. Beall, MD, ... drug therapy for patients living with relapsing and primary multiple sclerosis that can ... targeted therapy that has been proven to significantly reduce signs of disease activity ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there could ... Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK BRACKETS ... doing so, it offers an effective alternative to traditional braces. As a result, it ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
(Date:7/26/2017)... Wheaton, IL (PRWEB) , ... July 26, 2017 , ... Wendy M. Musielak, ... Cores LLP, was elected as DuPage County Bar Association’s third Vice President earlier this year. ... succeeding to the office of the second Vice President, in accordance with the organization’s by-laws. ...
Breaking Medicine News(10 mins):